NanoVibronix has announced the development of ENvue Drive, a robotic platform designed to enhance bedside feeding tube and vascular line navigation.
The initiative aims to automate electromagnetic navigation for enteral and vascular procedures, leveraging the company’s existing US Food and Drug Administration (FDA)-cleared technology.
The ENvue Drive platform is currently in the engineering development phase and is set to integrate with NanoVibronix’s electromagnetic guidance systems, enabling automated alignment and positional stability while retaining clinician control.
NanoVibronix and ENvue Medical CEO Doron Besser said: “ENvue’s Drive platform marks a transformative move for bedside clinical care.
“By embedding intelligent robotics into high frequency clinical workflows, starting with feeding tubes and expanding into vascular areas, we believe that we are addressing a major clinical challenge of doing more with fewer hands without compromising precision or safety while giving clinicians a new level of confidence and consistency in care.”
According to NanoVibronix, ENvue Drive is positioned as a supplementary tool for clinicians rather than a replacement, particularly in critical settings like ICUs and telemetry wards. The system’s development goals include automated probe alignment and real-time stabilised positioning during procedures, reducing reliance on multiple clinicians and increasing consistency.
The platform is in preclinical development with engineering prototypes underway and input from clinical advisers being sought. Regulatory submission to the FDA has not yet occurred, though NanoVibronix plans to initiate these processes later in the year with a goal to have a functional prototype by year-end.
Based in Tyler, Texas, NanoVibronix, focuses on non-invasive therapeutic systems. It operates across clinical settings with two main technology platforms: acoustic-based devices like PainShield and UroShield, and the ENvue Navigation Platform for electromagnetic navigation in medical procedures.
